Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the coming weeks

11/30/2020 | 06:31am EST

NEW YORK, Nov 30 (Reuters) - Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November.

It is the second time that Novavax, which already has a late-stage UK trial underway, has rescheduled the Phase 3 trial after first flagging an October start, hampered by issues in scaling up its manufacturing.

Novavax plans to use vaccine material produced at commercial scale for the trial in the United States and Mexico and has been working closely with the U.S. Food and Drug Administration to greenlight the use of the vaccine made at a North Carolina plant.

The company also said it has completed enrollment for its 15,000 participant UK trial and expects interim data as soon as the first quarter of 2021.

It has previously said that the UK trial could be the basis for some global regulatory approvals.

More than 25% of enrollees in the UK trial are over the age of 65, while a large proportion of volunteers had underlying co-morbid medical conditions generally representative of the population.

Novavax is also running a fully enrolled Phase 2b trial in South Africa, which has 4,400 volunteers including 245 who are medically stable, HIV positive participants. Efficacy data from that trial could also be available in the first quarter of next year. (Reporting by Michael Erman; Editing by Edwina Gibbs)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DOW JONES AFRICA TITANS 50 INDEX 0.60% 538.79 Delayed Quote.0.36%
NOVAVAX, INC. 0.45% 128 Delayed Quote.14.28%
S&P AFRICA 40 INDEX 0.90% 175.35 Delayed Quote.-0.21%
All news about NOVAVAX, INC.
07:31aJapan has pre-ordered COVID-19 vaccine doses for more than four times its pop..
AQ
06:38aPhilippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
RE
01/18Philippines to buy 20 mln doses of Moderna's COVID-19 vaccine
RE
01/18NOVAVAX : Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulat..
AQ
01/15Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory an..
GL
01/14Serum Institute expects WHO emergency approval for AstraZeneca shot soon
RE
01/14ASTRAZENECA : COVID-19 Vaccine To Win WHO's Emergency-Use Approval By 'Next Week..
MT
01/14MARKET CHATTER : South Korea Negotiates over Additional 20 Million COVID-19 Vacc..
MT
01/14ASTRAZENECA : Serum Institute expects WHO emergency approval for AstraZeneca sho..
RE
01/14Philippines approves Pfizer-BioNTech vaccine for emergency use
RE
More news
Financials (USD)
Sales 2020 520 M - -
Net income 2020 -314 M - -
Net cash 2020 465 M - -
P/E ratio 2020 -23,3x
Yield 2020 -
Capitalization 6 546 M 6 546 M -
EV / Sales 2020 11,7x
EV / Sales 2021 1,69x
Nbr of Employees 522
Free-Float 97,6%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 188,50 $
Last Close Price 128,00 $
Spread / Highest target 74,2%
Spread / Average Target 47,3%
Spread / Lowest Target -41,4%
EPS Revisions
Managers and Directors
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Richard Crowley Chief Operating Officer & Executive Vice President
Gregory F. Covino Chief Financial Officer & Executive Vice President
Gregory M. Glenn President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.14.28%6 516
MODERNA, INC.24.10%51 304
LONZA GROUP AG2.46%48 618
CELLTRION, INC.-12.95%38 786
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601